Matches in Nanopublications for { <http://www.w3.org/2000/01/rdf-schema#SENTENCE> ?p ?o ?g. }
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "Although patients with hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy generally experienced poor outcomes, etoposide + dexamethasone-based chemotherapy regimens were associated with good outcomes among select patients with newly diagnosed or stage I/II NK/T-LAHLH." provenance.
- SENTENCE label "However, using the 8 mg dexamethasone administered orally before the procedure seems to result in an improvement in the postoperative period of patients who had impacted teeth." provenance.
- SENTENCE label "However, using the 8 mg dexamethasone administered orally before the procedure seems to result in an improvement in the postoperative period of patients who had impacted teeth." provenance.
- SENTENCE label "However, using the 8 mg dexamethasone administered orally before the procedure seems to result in an improvement in the postoperative period of patients who had impacted teeth." provenance.
- SENTENCE label "However, using the 8 mg dexamethasone administered orally before the procedure seems to result in an improvement in the postoperative period of patients who had impacted teeth." provenance.
- SENTENCE label "However, using the 8 mg dexamethasone administered orally before the procedure seems to result in an improvement in the postoperative period of patients who had impacted teeth." provenance.
- SENTENCE label "However, using the 8 mg dexamethasone administered orally before the procedure seems to result in an improvement in the postoperative period of patients who had impacted teeth." provenance.
- SENTENCE label "However, using the 8 mg dexamethasone administered orally before the procedure seems to result in an improvement in the postoperative period of patients who had impacted teeth." provenance.
- SENTENCE label "However, using the 8 mg dexamethasone administered orally before the procedure seems to result in an improvement in the postoperative period of patients who had impacted teeth." provenance.
- SENTENCE label "However, using the 8 mg dexamethasone administered orally before the procedure seems to result in an improvement in the postoperative period of patients who had impacted teeth." provenance.
- SENTENCE label "However, using the 8 mg dexamethasone administered orally before the procedure seems to result in an improvement in the postoperative period of patients who had impacted teeth." provenance.
- SENTENCE label "However, using the 8 mg dexamethasone administered orally before the procedure seems to result in an improvement in the postoperative period of patients who had impacted teeth." provenance.
- SENTENCE label "However, using the 8 mg dexamethasone administered orally before the procedure seems to result in an improvement in the postoperative period of patients who had impacted teeth." provenance.
- SENTENCE label "However, using the 8 mg dexamethasone administered orally before the procedure seems to result in an improvement in the postoperative period of patients who had impacted teeth." provenance.
- SENTENCE label "However, using the 8 mg dexamethasone administered orally before the procedure seems to result in an improvement in the postoperative period of patients who had impacted teeth." provenance.
- SENTENCE label "However, using the 8 mg dexamethasone administered orally before the procedure seems to result in an improvement in the postoperative period of patients who had impacted teeth." provenance.
- SENTENCE label "However, using the 8 mg dexamethasone administered orally before the procedure seems to result in an improvement in the postoperative period of patients who had impacted teeth." provenance.
- SENTENCE label "Treatment of human peripheral blood mononuclear cells (PBMCs) with dexamethasone (100 nM) or BAY11-7082 (1 μM) resulted in inhibition of spike glycoprotein S1-induced NF-κB activation." provenance.
- SENTENCE label "Treatment of human peripheral blood mononuclear cells (PBMCs) with dexamethasone (100 nM) or BAY11-7082 (1 μM) resulted in inhibition of spike glycoprotein S1-induced NF-κB activation." provenance.
- SENTENCE label "Treatment of human peripheral blood mononuclear cells (PBMCs) with dexamethasone (100 nM) or BAY11-7082 (1 μM) resulted in inhibition of spike glycoprotein S1-induced NF-κB activation." provenance.
- SENTENCE label "Treatment of human peripheral blood mononuclear cells (PBMCs) with dexamethasone (100 nM) or BAY11-7082 (1 μM) resulted in inhibition of spike glycoprotein S1-induced NF-κB activation." provenance.
- SENTENCE label "Treatment of human peripheral blood mononuclear cells (PBMCs) with dexamethasone (100 nM) or BAY11-7082 (1 μM) resulted in inhibition of spike glycoprotein S1-induced NF-κB activation." provenance.
- SENTENCE label "Treatment of human peripheral blood mononuclear cells (PBMCs) with dexamethasone (100 nM) or BAY11-7082 (1 μM) resulted in inhibition of spike glycoprotein S1-induced NF-κB activation." provenance.
- SENTENCE label "Treatment of human peripheral blood mononuclear cells (PBMCs) with dexamethasone (100 nM) or BAY11-7082 (1 μM) resulted in inhibition of spike glycoprotein S1-induced NF-κB activation." provenance.
- SENTENCE label "Treatment of human peripheral blood mononuclear cells (PBMCs) with dexamethasone (100 nM) or BAY11-7082 (1 μM) resulted in inhibition of spike glycoprotein S1-induced NF-κB activation." provenance.
- SENTENCE label "Treatment of human peripheral blood mononuclear cells (PBMCs) with dexamethasone (100 nM) or BAY11-7082 (1 μM) resulted in inhibition of spike glycoprotein S1-induced NF-κB activation." provenance.
- SENTENCE label "The remaining treatment was the same for two groups of 30 patients each who had received either dexamethasone or methylprednisolone using antibiotics and anticoagulation." provenance.
- SENTENCE label "The remaining treatment was the same for two groups of 30 patients each who had received either dexamethasone or methylprednisolone using antibiotics and anticoagulation." provenance.
- SENTENCE label "The remaining treatment was the same for two groups of 30 patients each who had received either dexamethasone or methylprednisolone using antibiotics and anticoagulation." provenance.
- SENTENCE label "The remaining treatment was the same for two groups of 30 patients each who had received either dexamethasone or methylprednisolone using antibiotics and anticoagulation." provenance.
- SENTENCE label "The remaining treatment was the same for two groups of 30 patients each who had received either dexamethasone or methylprednisolone using antibiotics and anticoagulation." provenance.
- SENTENCE label "The remaining treatment was the same for two groups of 30 patients each who had received either dexamethasone or methylprednisolone using antibiotics and anticoagulation." provenance.
- SENTENCE label "After hypoxemia (late dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group." provenance.
- SENTENCE label "After hypoxemia (late dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group." provenance.
- SENTENCE label "After hypoxemia (late dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group." provenance.
- SENTENCE label "After hypoxemia (late dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group." provenance.
- SENTENCE label "After hypoxemia (late dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group." provenance.
- SENTENCE label "After hypoxemia (late dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group." provenance.
- SENTENCE label "After hypoxemia (late dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group." provenance.
- SENTENCE label "After hypoxemia (late dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group." provenance.
- SENTENCE label "After hypoxemia (late dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group." provenance.
- SENTENCE label "After hypoxemia (late dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group." provenance.
- SENTENCE label "After hypoxemia (late dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group." provenance.
- SENTENCE label "After hypoxemia (late dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group." provenance.
- SENTENCE label "Prostaglandin E2 (PGE2), synthesized primarily by astrocytes, increases GnRH neurons activity and downstream pituitary release of luteinizing hormone (LH)." provenance.
- SENTENCE label "Prostaglandin E2 (PGE2), synthesized primarily by astrocytes, increases GnRH neurons activity and downstream pituitary release of luteinizing hormone (LH)." provenance.
- SENTENCE label "Prostaglandin E2 (PGE2), synthesized primarily by astrocytes, increases GnRH neurons activity and downstream pituitary release of luteinizing hormone (LH)." provenance.
- SENTENCE label "Prostaglandin E2 (PGE2), synthesized primarily by astrocytes, increases GnRH neurons activity and downstream pituitary release of luteinizing hormone (LH)." provenance.
- SENTENCE label "Prostaglandin E2 (PGE2), synthesized primarily by astrocytes, increases GnRH neurons activity and downstream pituitary release of luteinizing hormone (LH)." provenance.
- SENTENCE label "Prostaglandin E2 (PGE2), synthesized primarily by astrocytes, increases GnRH neurons activity and downstream pituitary release of luteinizing hormone (LH)." provenance.
- SENTENCE label "Two of them (betamethasone and dexamethasone) interacted with both the catalytic residues of SARS CoV-2 Mpro, a key component of viral replication (His41 and Cys145)." provenance.
- SENTENCE label "Two of them (betamethasone and dexamethasone) interacted with both the catalytic residues of SARS CoV-2 Mpro, a key component of viral replication (His41 and Cys145)." provenance.
- SENTENCE label "Two of them (betamethasone and dexamethasone) interacted with both the catalytic residues of SARS CoV-2 Mpro, a key component of viral replication (His41 and Cys145)." provenance.
- SENTENCE label "Two of them (betamethasone and dexamethasone) interacted with both the catalytic residues of SARS CoV-2 Mpro, a key component of viral replication (His41 and Cys145)." provenance.
- SENTENCE label "Two of them (betamethasone and dexamethasone) interacted with both the catalytic residues of SARS CoV-2 Mpro, a key component of viral replication (His41 and Cys145)." provenance.
- SENTENCE label "Two of them (betamethasone and dexamethasone) interacted with both the catalytic residues of SARS CoV-2 Mpro, a key component of viral replication (His41 and Cys145)." provenance.
- SENTENCE label "Population analysis of pharmacokinetic data for five differing dosage forms and routes for dexamethasone and betamethasone in 48 healthy nonpregnant Indian women was performed that accounted for a partial and complex cross-over design." provenance.
- SENTENCE label "Population analysis of pharmacokinetic data for five differing dosage forms and routes for dexamethasone and betamethasone in 48 healthy nonpregnant Indian women was performed that accounted for a partial and complex cross-over design." provenance.
- SENTENCE label "Population analysis of pharmacokinetic data for five differing dosage forms and routes for dexamethasone and betamethasone in 48 healthy nonpregnant Indian women was performed that accounted for a partial and complex cross-over design." provenance.
- SENTENCE label "Population analysis of pharmacokinetic data for five differing dosage forms and routes for dexamethasone and betamethasone in 48 healthy nonpregnant Indian women was performed that accounted for a partial and complex cross-over design." provenance.
- SENTENCE label "Population analysis of pharmacokinetic data for five differing dosage forms and routes for dexamethasone and betamethasone in 48 healthy nonpregnant Indian women was performed that accounted for a partial and complex cross-over design." provenance.
- SENTENCE label "Population analysis of pharmacokinetic data for five differing dosage forms and routes for dexamethasone and betamethasone in 48 healthy nonpregnant Indian women was performed that accounted for a partial and complex cross-over design." provenance.
- SENTENCE label "Population analysis of pharmacokinetic data for five differing dosage forms and routes for dexamethasone and betamethasone in 48 healthy nonpregnant Indian women was performed that accounted for a partial and complex cross-over design." provenance.
- SENTENCE label "Population analysis of pharmacokinetic data for five differing dosage forms and routes for dexamethasone and betamethasone in 48 healthy nonpregnant Indian women was performed that accounted for a partial and complex cross-over design." provenance.
- SENTENCE label "Population analysis of pharmacokinetic data for five differing dosage forms and routes for dexamethasone and betamethasone in 48 healthy nonpregnant Indian women was performed that accounted for a partial and complex cross-over design." provenance.
- SENTENCE label "Population analysis of pharmacokinetic data for five differing dosage forms and routes for dexamethasone and betamethasone in 48 healthy nonpregnant Indian women was performed that accounted for a partial and complex cross-over design." provenance.
- SENTENCE label "Population analysis of pharmacokinetic data for five differing dosage forms and routes for dexamethasone and betamethasone in 48 healthy nonpregnant Indian women was performed that accounted for a partial and complex cross-over design." provenance.
- SENTENCE label "Population analysis of pharmacokinetic data for five differing dosage forms and routes for dexamethasone and betamethasone in 48 healthy nonpregnant Indian women was performed that accounted for a partial and complex cross-over design." provenance.
- SENTENCE label "Population analysis of pharmacokinetic data for five differing dosage forms and routes for dexamethasone and betamethasone in 48 healthy nonpregnant Indian women was performed that accounted for a partial and complex cross-over design." provenance.
- SENTENCE label "Population analysis of pharmacokinetic data for five differing dosage forms and routes for dexamethasone and betamethasone in 48 healthy nonpregnant Indian women was performed that accounted for a partial and complex cross-over design." provenance.
- SENTENCE label "Population analysis of pharmacokinetic data for five differing dosage forms and routes for dexamethasone and betamethasone in 48 healthy nonpregnant Indian women was performed that accounted for a partial and complex cross-over design." provenance.
- SENTENCE label "Population analysis of pharmacokinetic data for five differing dosage forms and routes for dexamethasone and betamethasone in 48 healthy nonpregnant Indian women was performed that accounted for a partial and complex cross-over design." provenance.
- SENTENCE label "Population analysis of pharmacokinetic data for five differing dosage forms and routes for dexamethasone and betamethasone in 48 healthy nonpregnant Indian women was performed that accounted for a partial and complex cross-over design." provenance.
- SENTENCE label "Population analysis of pharmacokinetic data for five differing dosage forms and routes for dexamethasone and betamethasone in 48 healthy nonpregnant Indian women was performed that accounted for a partial and complex cross-over design." provenance.
- SENTENCE label "Population analysis of pharmacokinetic data for five differing dosage forms and routes for dexamethasone and betamethasone in 48 healthy nonpregnant Indian women was performed that accounted for a partial and complex cross-over design." provenance.
- SENTENCE label "Population analysis of pharmacokinetic data for five differing dosage forms and routes for dexamethasone and betamethasone in 48 healthy nonpregnant Indian women was performed that accounted for a partial and complex cross-over design." provenance.
- SENTENCE label "Population analysis of pharmacokinetic data for five differing dosage forms and routes for dexamethasone and betamethasone in 48 healthy nonpregnant Indian women was performed that accounted for a partial and complex cross-over design." provenance.
- SENTENCE label "Population analysis of pharmacokinetic data for five differing dosage forms and routes for dexamethasone and betamethasone in 48 healthy nonpregnant Indian women was performed that accounted for a partial and complex cross-over design." provenance.
- SENTENCE label "Population analysis of pharmacokinetic data for five differing dosage forms and routes for dexamethasone and betamethasone in 48 healthy nonpregnant Indian women was performed that accounted for a partial and complex cross-over design." provenance.
- SENTENCE label "Population analysis of pharmacokinetic data for five differing dosage forms and routes for dexamethasone and betamethasone in 48 healthy nonpregnant Indian women was performed that accounted for a partial and complex cross-over design." provenance.
- SENTENCE label "Population analysis of pharmacokinetic data for five differing dosage forms and routes for dexamethasone and betamethasone in 48 healthy nonpregnant Indian women was performed that accounted for a partial and complex cross-over design." provenance.
- SENTENCE label "Population analysis of pharmacokinetic data for five differing dosage forms and routes for dexamethasone and betamethasone in 48 healthy nonpregnant Indian women was performed that accounted for a partial and complex cross-over design." provenance.
- SENTENCE label "Population analysis of pharmacokinetic data for five differing dosage forms and routes for dexamethasone and betamethasone in 48 healthy nonpregnant Indian women was performed that accounted for a partial and complex cross-over design." provenance.
- SENTENCE label "Only glucocorticoids, dexamethasone and hydrocortisone, were associated with a significant reduction in mortality of patients with ARDS due to COVID-19, most probably via non-specific anti-inflammatory effects." provenance.
- SENTENCE label "Only glucocorticoids, dexamethasone and hydrocortisone, were associated with a significant reduction in mortality of patients with ARDS due to COVID-19, most probably via non-specific anti-inflammatory effects." provenance.
- SENTENCE label "Only glucocorticoids, dexamethasone and hydrocortisone, were associated with a significant reduction in mortality of patients with ARDS due to COVID-19, most probably via non-specific anti-inflammatory effects." provenance.
- SENTENCE label "Only glucocorticoids, dexamethasone and hydrocortisone, were associated with a significant reduction in mortality of patients with ARDS due to COVID-19, most probably via non-specific anti-inflammatory effects." provenance.
- SENTENCE label "Only glucocorticoids, dexamethasone and hydrocortisone, were associated with a significant reduction in mortality of patients with ARDS due to COVID-19, most probably via non-specific anti-inflammatory effects." provenance.
- SENTENCE label "Only glucocorticoids, dexamethasone and hydrocortisone, were associated with a significant reduction in mortality of patients with ARDS due to COVID-19, most probably via non-specific anti-inflammatory effects." provenance.
- SENTENCE label "Only glucocorticoids, dexamethasone and hydrocortisone, were associated with a significant reduction in mortality of patients with ARDS due to COVID-19, most probably via non-specific anti-inflammatory effects." provenance.
- SENTENCE label "Only glucocorticoids, dexamethasone and hydrocortisone, were associated with a significant reduction in mortality of patients with ARDS due to COVID-19, most probably via non-specific anti-inflammatory effects." provenance.
- SENTENCE label "Only glucocorticoids, dexamethasone and hydrocortisone, were associated with a significant reduction in mortality of patients with ARDS due to COVID-19, most probably via non-specific anti-inflammatory effects." provenance.
- SENTENCE label "Only glucocorticoids, dexamethasone and hydrocortisone, were associated with a significant reduction in mortality of patients with ARDS due to COVID-19, most probably via non-specific anti-inflammatory effects." provenance.
- SENTENCE label "Only glucocorticoids, dexamethasone and hydrocortisone, were associated with a significant reduction in mortality of patients with ARDS due to COVID-19, most probably via non-specific anti-inflammatory effects." provenance.